Polycomb target genes are silenced in multiple myeloma

Multiple myeloma (MM) is a genetically heterogeneous disease, which to date remains fatal. Finding a common mechanism for initiation and progression of MM continues to be challenging. By means of integrative genomics, we identified an underexpressed gene signature in MM patient cells compared to nor...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 5; no. 7; p. e11483
Main Authors Kalushkova, Antonia, Fryknäs, Mårten, Lemaire, Miguel, Fristedt, Charlotte, Agarwal, Prasoon, Eriksson, Maria, Deleu, Sarah, Atadja, Peter, Osterborg, Anders, Nilsson, Kenneth, Vanderkerken, Karin, Oberg, Fredrik, Jernberg-Wiklund, Helena
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 09.07.2010
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Multiple myeloma (MM) is a genetically heterogeneous disease, which to date remains fatal. Finding a common mechanism for initiation and progression of MM continues to be challenging. By means of integrative genomics, we identified an underexpressed gene signature in MM patient cells compared to normal counterpart plasma cells. This profile was enriched for previously defined H3K27-tri-methylated genes, targets of the Polycomb group (PcG) proteins in human embryonic fibroblasts. Additionally, the silenced gene signature was more pronounced in ISS stage III MM compared to stage I and II. Using chromatin immunoprecipitation (ChIP) assay on purified CD138+ cells from four MM patients and on two MM cell lines, we found enrichment of H3K27me3 at genes selected from the profile. As the data implied that the Polycomb-targeted gene profile would be highly relevant for pharmacological treatment of MM, we used two compounds to chemically revert the H3K27-tri-methylation mediated gene silencing. The S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin (DZNep) and the histone deacetylase inhibitor LBH589 (Panobinostat), reactivated the expression of genes repressed by H3K27me3, depleted cells from the PRC2 component EZH2 and induced apoptosis in human MM cell lines. In the immunocompetent 5T33MM in vivo model for MM, treatment with LBH589 resulted in gene upregulation, reduced tumor load and increased overall survival. Taken together, our results reveal a common gene signature in MM, mediated by gene silencing via the Polycomb repressor complex. The importance of the underexpressed gene profile in MM tumor initiation and progression should be subjected to further studies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Conceived and designed the experiments: AK MF ML CF KV FÖ HJW. Performed the experiments: AK MF ML CF PA ME SD. Analyzed the data: AK MF ML CF PA. Contributed reagents/materials/analysis tools: PA AÖ. Wrote the paper: AK. Supervised the project, interpreted data and edited the manuscript: HJW KV FÖ. Developed the concept, performed the integrative genomics analysis and interpreted data: MF. Provided clinical expertise: AÖ. Edited the manuscript: KN.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0011483